🥇 First rule of investing? Know when to save! Up to 55% off Investing Pro before BLACK FRIDAYCLAIM SALE

Teva Pharma Industries Ltd ADR (TEVA)

NYSE
Currency in USD
17.37
+0.26(+1.52%)
Closed
After Hours
17.370.00(0.00%)
TEVA Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
17.1417.51
52 wk Range
8.5519.31
Key Statistics
Edit
Prev. Close
17.11
Open
17.4
Day's Range
17.14-17.51
52 wk Range
8.55-19.31
Volume
6,993,201
Average Volume (3m)
6,624,396
1-Year Change
97.12%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TEVA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
22.36
Upside
+28.73%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period
Show more

Teva ADR Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Employees
35737

InvestingPro Research for Teva Pharma Industries Ltd ADR


Strategic Shift
Explore Teva's pivot to biosimilars and complex generics, positioning the company for growth amid patent cliffs and increasing demand for cost-effective treatments.
Financial Resilience
Teva's Q2 2024 results surpassed expectations, driven by Austedo's 32% YoY growth and Global Generic X's 14% increase, signaling a potential long-term uptrend.
Pipeline Potential
Delve into Teva's robust pipeline, including Olanzapine LAI and Anti-TLA1, poised to diversify revenue streams and enhance market position in specialty medicines.
Market Outlook
Analysts maintain a positive stance on Teva, with price targets ranging from $17 to $22, reflecting confidence in the company's growth strategy and market potential.
Read full SWOT analysis

Compare TEVA to Peers and Sector

Metrics to compare
TEVA
Peers
Sector
Relationship
P/E Ratio
−20.5x−2.7x−0.6x
PEG Ratio
−0.34−0.080.00
Price/Book
3.2x1.5x2.6x
Price / LTM Sales
1.2x2.6x3.2x
Upside (Analyst Target)
34.4%306.5%43.4%
Fair Value Upside
Unlock14.5%6.4%Unlock

FAQ

What Is the Teva ADR (TEVA) Stock Price Today?

The Teva ADR stock price today is 17.37.

What Stock Exchange Does Teva ADR Trade On?

Teva ADR is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Teva ADR?

The stock symbol for Teva ADR is "TEVA."

What Is the Teva ADR Market Cap?

As of today, Teva ADR market cap is 19.39B.

What is Teva ADR Earnings Per Share?

The Teva ADR EPS is -0.851.

What Is the Next Teva ADR Earnings Date?

Teva ADR will release its next earnings report on 04 Feb 2025.

From a Technical Analysis Perspective, Is TEVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.